LINC01546: A Drug Target / Disease Biomarker (G100129464)

Target Name: LINC01546

NCBI ID: G100129464

LINC01546

Other Name(s): Long intergenic non-protein coding RNA 1546 | VAL | long intergenic non-protein coding RNA 1546 | CXorf28

LINC01546: A Drug Target / Disease Biomarker

LINC01546 is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 18 and encodes a protein known as NIP (nitrosyl-protein inhibitor).

NIP is a protein that plays a critical role in the regulation of cellular processes that are involved in cell growth, apoptosis (programmed cell death), and inflammation. It is known for its ability to inhibit the activity of the protein IMP (inositol-dependent protein kinase), which is involved in the production of insulin and other signaling molecules that promote cell growth and survival.

In addition to its role in cell signaling, NIP is also involved in the regulation of inflammation. It has been shown to play a key role in the regulation ofT cells, which are a type of immune cell that play a critical role in the immune system. T cells are involved in the production of antibodies, which are proteins that help to neutralize or destroy pathogens in the body.

The potential drug target for NIP is its ability to inhibit the activity of IMP, which is a key regulator of cell signaling. This has led to the hypothesis that NIP may be an effective drug target for diseases that are characterized by the over-production or dysfunction of IMP.

One of the primary targets for NIP is the production of cancer cells. Cancer cells are characterized by the over-production of IMP, which allows them to survive and divide uncontrollably. NIP has been shown to inhibit the production of IMP in cancer cells, which has led to the potential for it to be an effective drug for the treatment of cancer.

In addition to its potential use as a cancer drug, NIP has also been identified as a potential biomarker for the disease. The over-production of IMP in cancer cells can be detected using NIP as a target, which allows for the diagnosis of cancer. This has the potential to improve the accuracy and speed of cancer diagnosis, as well as the development of new treatments.

Another potential application for NIP is its use as an anti-inflammatory drug. The over-production of IMP in inflammatory cells, such as T cells, has been implicated in the development and progression of a number of inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and asthma. NIP has been shown to inhibit the production of IMP in these cells, which has the potential for it to be an effective drug for the treatment of these diseases.

In conclusion, LINC01546 is a gene that has the potential to be a drug target or biomarker for the treatment of a variety of diseases. Its role in the regulation of cell signaling and inflammation makes it an attractive target for the development of new treatments. Further research is needed to fully understand the potential of NIP as a drug and biomarker, and to develop safe and effective treatments for the treatment of a wide range of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1546

The "LINC01546 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01546 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets